Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib with or without vinorelbine versus investigator's choice for HER2-positive breast cancer with progressive brain metastases
2010-021415-16Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of afatinib and vinorelbine in breast cancer (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Patient benefit at 12 weeks. Started Jul 2011; status: completed.
02
Drugs
afatinibvinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-021415-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021415-16.